Immuneel Therapeutics raises over Rs 100 cr in Series B funding
Business 08 Jun, 2026

Immuneel Therapeutics raises over Rs 100 cr in Series B funding

Business To Business, New Delhi, 8th June, 2026:  Bengaluru-based cell and gene therapy company Immuneel Therapeutics has raised more than ₹100 crore in a Series B funding round, strengthening investor confidence in India's emerging advanced cancer therapy sector.
Investors in the Round
The funding round was backed by a mix of new and existing investors:
New investors

Existing investors According to the company, the fresh capital will be deployed to:
  1. Expand its GMP (Good Manufacturing Practice) manufacturing capacity.
  2. Advance its next-generation cell and gene therapy pipeline toward clinical milestones.
  3. Support the commercialization of Qartemi, India's first approved CAR-T therapy for Non-Hodgkin Lymphoma.
  4. Accelerate international expansion across the Asia-Pacific and West Asia (Middle East) regions.
Immuneel is one of India's leading companies working on CAR-T (Chimeric Antigen Receptor T-cell) therapy, an advanced cancer treatment that modifies a patient's immune cells to attack cancer. While CAR-T therapies have shown significant success globally, they have traditionally been extremely expensive and difficult to manufacture. Immuneel's strategy focuses on making these therapies more accessible and affordable for patients in India and other emerging markets.
The funding signals growing investor interest in India's deep-science biotechnology ecosystem. Beyond scaling Qartemi, the company plans to develop additional cell and gene therapies for blood cancers and other oncology indications, while building a globally competitive CAR-T manufacturing platform from India.
This is one of the larger funding rounds in India's cell and gene therapy space in 2026 and highlights increasing momentum for advanced oncology treatments developed and manufactured domestically.

Related News